Search results
Results from the WOW.Com Content Network
Negative interim PET scan results probably result in a large increase in the overall survival compared to those with a positive interim PET scan result. [ 62 ] Current research evaluated whether Nivolumab can be used for the treatment of a Hodgkin's lymphoma.
The evidence is very uncertain about the effect of negative (= good prognosis) or positive (= bad prognosis) interim PET scan results for patients with a Hodgkin's lymphoma on the progression-free survival. Negative interim PET scan results may result in an increase in progression-free survival compared if the adjusted result was measured.
A 2020 review of research on the use of PET for Hodgkin lymphoma found evidence that negative findings in interim PET scans are linked to higher overall survival and progression-free survival; however, the certainty of the available evidence was moderate for survival, and very low for progression-free survival. [11]
Within the four groups for NHL are over 60 specific types of lymphoma. [8] [9] Diagnosis is by examination of a bone marrow or lymph node biopsy. [1] Medical imaging is done to help with cancer staging. [1] Treatment depends on whether the lymphoma is slow- or fast-growing and if it is in one area or many areas. [1]
Progression-free survival (PFS) is "the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse". [1] In oncology , PFS usually refers to situations in which a tumor is present, as demonstrated by laboratory testing, radiologic testing, or clinically.
>30% increase in 18F-FDG SUL peak, with >0.8 SUL units increase in tumor SUV peak from the baseline scan in pattern typical of tumor and not of infection/treatment effect. or Visible increase in the extent of 18F-FDG tumor uptake. or New 18F-FDG avid lesions which are typical of cancer and not related to treatment effect or infection.
In the United States during 2013–2017, the age-adjusted mortality rate for all types of cancer was 189.5/100,000 for males, and 135.7/100,000 for females. [1] Below is an incomplete list of age-adjusted mortality rates for different types of cancer in the United States from the Surveillance, Epidemiology, and End Results program.
A simplified index can be used when comparing patients within an age group (i.e. 60 or younger, or over 60) and includes only 3 of the above factors: [citation needed] Stage; LDH; Performance status; The sum of the points allotted correlates with the following risk groups: Low risk (0 points) - 5-year survival of 83%